Literature DB >> 12472451

The management of normal tension glaucoma.

Julian Sack1.   

Abstract

OBJECTIVE: To outline the difficulties in making management decisions associated with normal tension glaucoma. To suggest treatment strategies according to the clinical presentation of the disease.
METHOD: Literature review and findings based on clinical experience.
CONCLUSIONS: The treatment of normal tension glaucoma involves many difficult decisions including whether to intervene and, if so, when and how to treat. Providing the patient with information is essential to gain co-operation and confidence. At present, the treatment objectives are to prevent further visual field loss by reduction of intraocular pressure by 30 per cent or more. This may be achieved by using medical or surgical regimens. Recently, there has been emphasis on the use of neuroprotective drugs that may act independently of the effect of intraocular pressure lowering. The balance between protecting vision and iatrogenic damage is not always easy.

Entities:  

Year:  2000        PMID: 12472451     DOI: 10.1111/j.1444-0938.2000.tb04913.x

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  3 in total

1.  An hypothesis on pressure transmission from anterior chamber to optic nerve.

Authors:  Rosana Gerometta; D Escobar; Oscar A Candia
Journal:  Med Hypotheses       Date:  2011-08-19       Impact factor: 1.538

2.  Comparison of ganglion cell and retinal nerve fiber layer thickness in primary open-angle glaucoma and normal tension glaucoma with spectral-domain OCT.

Authors:  Penpe Gul Firat; Selim Doganay; Ersan Ersin Demirel; Cemil Colak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-18       Impact factor: 3.117

3.  iStent Trabecular Micro-bypass Stent Implantation Combined with Phacoemulsification for Open-Angle Glaucoma: A 2-Year Post-marketing Surveillance Study in Japan.

Authors:  Masaru Inatani; Ichiro Kohama; Alice Chu
Journal:  Adv Ther       Date:  2022-07-05       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.